Cost-effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C;Rapporto costo-efficacia della terapia peginterferone α-2a + ribavirina in confronto a interferone α-2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati

PharmacoEconomics - Italian Research Articles

Volumn 6, Issue 2, 2004, Pages 105-114

  Sullivan, Sean D ^a   Craxi A ^b   Alberti, A ^c   Giuliani, G ^d   De Carli, C ^d   Wintfeld, N ^e   Patel, K K ^a,e   Green, J ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d ROCHE MILANO RICERCHE   (Italy)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE MODEL; DRUG COST; ECONOMIC ASPECT; FIBROSIS; FOLLOW UP; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIFE EXPECTANCY; LIVER CIRRHOSIS; MALE; NATIONAL HEALTH SERVICE; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

EID: 2942695736     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320628     Document Type: Article

References (37)

1. Global surveillance and control of hepatitis C: report of a WHO consultation. J Viral Hepat 1999; 6: 35-47
2. Mele A, Spada E. Epidemiologia delle infezioni acute da virus epatitici a transmissione parenterale. In: V Seminario di aggiornamento sull'epatite da virus HCV e nuovi virus potenzialmente epatitici: diagnosi, epidemiologia, prevenzione e terapia. Roma: ISS, Rapporti ISTISAN 00/32, 2000
3. Squarcione S, Carbini R, D'Amato S, et al. Epatite C in Italia nel 1992: analisi delle schede individuali. Ann Ig 1995; 7: 343-8
4. Farci P. Implicazioni biologiche e cliniche della quasispecie virale. In: V Seminario di aggiornamento sull'epatite da virus HCV e nuovi virus potenzialmente epatitici: diagnosi, epidemiologia, prevenzione e terapia. Roma: ISS, Rapporti ISTISAN 00/32, 2000
5. Ministero della Sanità - Dipartimento per la Valutazione dei Medicinali e la Farmacovigilanza. Ribavirina - interferone: una terapia per l'epatite cronica C. Boll Informazione Farmaci 2000; 3: 8-17
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32
7. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36 (Suppl.): S114-20
8. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng] J Med 1998; 339 (21): 1485-92
9. Pol S, Nalpas B, Bouriliere M, et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31: 1338-44
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
11. Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000; 33: 651-8
12. Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 and 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C: International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95: 1524-30
13. Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870-6
14. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50: 253-8
15. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
16. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 53: 425-32
17. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32
18. Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318-24
19. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003; 60 (2): 145-50
20. Ministero della Sanità - Dipartimento per la Valutazione dei Medicinali e ]a Farmacovigilanza. Documento su: programma informazione sui farmaci, farmacovigilanza ed educazione sanitaria. Allegato 1: Epatite C - Ribavirina. 19 Nov 1999 [online]. Disponibile da URL: http://www.ministerosalute.it/medicinali/notizie/file/ Informazione_farmaci.pdf [Accesso 2004 Feb 4]
21. Ferenci P, Shiffman ML, Fried MW, et al. Early prediction of response to 40 kDa peginterferon alfa-2a (Pegasys) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC) [abstract]. Hepatology 2001; 34: 351A
22. Yano M, Kumada H, Kage ME, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40
23. Fattovich G, Giustina G, Degos F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 1997; 112: 463-72
24. Ascher NL, Lake JR, Emend J, et al. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20: 245-75
25. Detre KM, Belle SH, Lomardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996; 2: 2219-28
26. Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplantation experience from 37 transplant centers as reported to Medicare. Transplantation 1993; 56: 554-61
27. National Center for Health Statistics. Vital statistics of the United States, 1997. Mortality, pt A vol. 2. Washington, DC: Public Health Service, 1998
28. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65
29. Younossi Z, McCormick M, Boparai N, et al. Impact of chronic liver disease on patients' utilities [abstract]. Gastroenterology 1999; 116: A1292
30. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 48 weeks of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-74
31. Munari L, Picciotto A. Recombinant interferon alfa-2b therapy of chronic hepatitis C in Italy: an economic analysis. FORUM Trends Exp Clin Med 1996; 6: 347-53
32. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290 (2): 228-37
33. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16
34. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81
35. Lau DT-Y, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-7
36. McHutchison JG, Davis GL, Esteben-Mur R, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon α-2b alone or in combination with ribavirin [abstract]. Hepatology 2001; 34: 244A
37. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-55